Blog

IVIG

IVIG for Immune Checkpoint Inhibitor-Related Toxicity

Patient receiving IVIG at home for Immune checkpoint inhibitor-related Toxicity

Immune checkpoint inhibitors (ICIs) are potent drug agents that stimulate long-lasting immune responses against cancer. ICI immunotherapy has revolutionized treatment procedures for cancer and now has become an effective option for patients with advanced or hard-to-treat (aggressive) cancers. 

Consultați un specialist în imunoglobulină (IVIG)

(877) 778-0318

However, these anti-cancer agents can sometimes overstimulate the immune response and cause several adverse effects, also known as immune-related adverse events (irAEs) or immune checkpoint inhibitor-related toxicity. ICI-related toxicity can impact all organs, but the skin, digestive, and endocrine organs are more frequently affected. 

If you or someone you know are experiencing severe-to-moderate immune checkpoint-related toxicity, then Terapia cu imunoglobulină intravenoasă (IVIG) can be considered to manage these toxicities (or irAEs). This article briefly explains what immune checkpoint inhibitors are, the toxicities they cause, and how IVIG can help manage them. 

What Are Immune Checkpoint Inhibitors?

Normally, your immune system has immune checkpoints, which are the proteins that act like a brake to stop the immune cells from attacking normal healthy cells. However, some cancer cells can evade destruction by producing their own checkpoint proteins.

When a cancer cell’s checkpoint proteins bind to the T-cell’s checkpoint proteins, they turn off the T-cells — as a result, cancer cells continue to grow and spread. 

Immune checkpoint inhibitors (ICIs) block these proteins on the T-cell and cancer cells. This turns on the T-cells and allows them to kill the cancer cells effectively. 

Though ICIs have successfully treated certain cancers like myeloma, kidney, or lung cancer, they can sometimes overstimulate the immune system, leading to immune checkpoint inhibitor-related toxicity or immune-related adverse events. The toxicity occurs early and typically happens weeks to 3 months after starting immune checkpoint blockers. 

The type of ICIs you’ve received can affect and cause inflammation in any organ in the body. Some of the affected organs with side effects (toxicities) include:

  • Skin (Dermatitis, seen in 40% to 60% of cases)
  • Lungs (Pneumonitis, seen in 5% of cases)
  • Endocrine system (Hypothyroidism, seen in 6% of cases)
  • Gastrointestinal system (Severe colitis, seen in 2% to 7% of cases)
  • Liver (Hepatitis, seen in 5% to 10% of cases) 
  • Neurological complications (Meningoencephalitis, miastenia gravis, and peripheral neuropathy, seen in 1% to 5% of cases)

Each patient responds to ICI immunotherapy differently. The toxicities of ICIs can vary among cancer patients and may range from mild to severely fatal. Therefore, a standard treatment is required to manage immune checkpoint inhibitor-related toxicity without completely shutting down its effect on fighting cancer. 

Healthcare providers treat immune checkpoint inhibitor-related toxicity depending on their severity. For instance, mild cases are usually managed with supportive care and careful monitoring. In most cases, corticosteroids (e.g., prednisone) are given to manage moderate to severe cases. 

In some cases, when the patients do not respond to steroids, then immunosuppressive drugs like mycophenolate mofetil or infliximab are used in the treatment plan for these patients. 

Vorbește cu un specialist

Despre asistența pentru coplată
Începeți

IVIG therapy can be used as an additional treatment in some severe cases of immune checkpoint inhibitor-related toxicity. For instance, one raport de caz demonstrated that high-dose steroid therapy and IVIG treatment resolved immune checkpoint inhibitor-related toxicity in a non-small cell lung cancer patient who experienced esophagitis, gastritis, and myocarditis after taking ICIs (e.g., pembrolizumab). 

IVIG modulates the overstimulated immune system in multiple ways: 

It Neutralizes Autoantibodies 

IVIG therapy neutralizes the autoantibodies that are produced by ICIs due to an overstimulated immune system. It counteracts the effects of these autoantibodies.

It Reduces Inflammation

Since IVIG has anti-inflammatory effects, it also helps to reduce inflammation caused by hyperactive immunological responses due to ICIs. 

It Prevents Tissue Damage

IVIG prevents tissue damage by stopping additional immunological attacks. 

In short, IVIG helps patients manage the harmful toxicities of immune checkpoint inhibitors (ICIs) while stabilizing the immune system. This allows patients to benefit from their cancer treatment with ICIs without affecting their immune response.

Patient receiving IVIG at home

IVIG is not a first-line treatment for immune checkpoint inhibitor-related toxicity and is only recommended under certain conditions:

IVIG is considered for immune checkpoint inhibitor-related toxicity for two main reasons: 

  • First, IVIG has a rapid response, which means it works quickly and can manage severe or refractory ICI-related toxicities. 
  • Second, IVIG targets specific parts of the immune system and does not interfere with the effectiveness of ICIs, unlike other immunosuppressive drugs. 

Obțineți autorizație prealabilă pentru IVIG

(877) 778-0318

The dose of IVIG can vary among patients and the type of toxicity they are experiencing. For instance, intravenous immunoglobulins can be given at a dose of 2 g/kg (0.4 g/kg/day over 5 days) to treat ICI-induced toxic epidermal necrolysis (a type of skin condition), pneumonitis (a type of lung condition), miastenia gravisși GBS

Patients who received IVIG treatment showed significant improvement in their condition. However, IVIG can cause some efecte secundare, such as headache, fever, nausea, and allergic reactions. 

Concluzie

Though Immune checkpoint inhibitors (ICIs) are considered effective for treating aggressive cancers, they also cause toxicities (side effects) in some patients by overstimulating the immune system. 

If you or your loved one are experiencing any unusual symptoms or ICI-associated toxicity, IVIG therapy may help manage these toxicities. IVIG does this by modulating the overactive immune system without disrupting the working mechanism of ICI in fighting cancer. 

It is recommended to consult your healthcare provider to get a customized plan of IVIG according to your ICI-related toxicity.

REFERINȚE:

  1. Durrechou, Q., Domblides, C., Sionneau, B., Lefort, F., Quivy, A., Ravaud, A., Gross-Goupil, M., & Daste, A. (2020). Management of Immune Checkpoint Inhibitor Toxicities. Cancer Management and Research, 12, 9139. https://doi.org/10.2147/CMAR.S218756
  2. Conroy, M., & Naidoo, J. (2022). Immune-related adverse events and the balancing act of immunotherapy. Nature Communications, 13(1), 1-4. https://doi.org/10.1038/s41467-022-27960-2
  3. Kian, W., Zemel, M., Elobra, F., Sharb, A. A., Levitas, D., Assabag, Y., Alguayn, F., Yakobson, A., Rouvinov, K., & Fuchs, L. (2021). Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anti-Cancer Drugs, 33(1), e738. https://doi.org/10.1097/CAD.0000000000001162
  4. Haanen, J., Carbonnel, F., Robert, C., Kerr, K., Peters, S., Larkin, J., & Jordan, K. (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28, iv119-iv142. https://doi.org/10.1093/annonc/mdx225
  5. Sullivan, R. J., & Weber, J. S. (2022). Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 21(7), 495-508. https://doi.org/10.1038/s41573-021-00259-5
  6. Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., Elshoury, A., Gesthalter, Y., Hegde, A., Jain, M., Kaffenberger, B. H., Lechner, M. G., Li, T., Marr, A., McGettigan, S., . . . Hang, L. (2022). Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(4), 387–405. https://doi.org/10.6004/jnccn.2022.0020
  7. Haugh, A. M., Probasco, J. C., & Johnson, D. B. (2020). Neurologic complications of immune checkpoint inhibitors. Expert Opinion on Drug Safety, 19(4), 479–488. https://doi.org/10.1080/14740338.2020.1738382
  8. Marin-Acevedo, J. A., Chirila, R. M., & Dronca, R. S. (2019). Immune checkpoint inhibitor toxicities. Mayo Clinic Proceedings, 94(7), 1321–1329. https://doi.org/10.1016/j.mayocp.2019.03.01
Aceste informații nu înlocuiesc sfatul sau tratamentul medical. Discutați cu medicul dumneavoastră sau cu furnizorul de servicii medicale despre afecțiunea dumneavoastră medicală înainte de a începe orice tratament nou. AmeriPharma® Specialty Care nu își asumă nicio răspundere pentru informațiile furnizate sau pentru orice diagnostic sau tratament efectuat ca urmare a acestuia și nici nu este responsabil pentru fiabilitatea conținutului. AmeriPharma® Specialty Care nu operează toate site-urile web/organizațiile enumerate aici și nici nu este responsabil pentru disponibilitatea sau fiabilitatea conținutului acestora. Aceste listări nu implică și nu constituie o aprobare, sponsorizare sau recomandare din partea AmeriPharma® Specialty Care. Această pagină web poate conține referințe la medicamente eliberate pe bază de rețetă, care sunt mărci comerciale sau mărci comerciale înregistrate ale producătorilor farmaceutici care nu sunt afiliați cu AmeriPharma® Specialty Care.
REVIZUIT MEDICAL DE Dr. Christine Leduc, doctor în farmacii

Dr. Christine Leduc, doctor în farmacii, s-a născut și a crescut în Irvine, California. A urmat facultatea la Universitatea Midwestern, unde a absolvit cu distincție cum laude. Cea mai satisfăcătoare parte a slujbei sale este sugerarea schimbărilor în stilul de viață, educarea pacienților cu privire la modul în care funcționează medicamentele lor și îndrumarea viitorilor farmaciști. Domeniile sale de expertiză sunt serviciul clienți și cunoașterea medicamentelor de specialitate. Având experiență în domeniul serviciilor în trecut, a dobândit abilitățile de serviciu clienți necesare pentru a înțelege nevoile pacienților săi. Dr. Leduc învață în prezent studenți de la Universitatea Marshall B. Ketchum, Universitatea din Kansas și Universitatea Midwestern. În timpul liber, îi place să călătorească, să coacă și să grădinărească.Vezi biografia autorului

Contactaţi-ne

Folosiți formularul conform HIPAA de mai jos pentru a solicita o reînnoire a rețetei dumneavoastră. Dacă aveți întrebări despre medicamentul dumneavoastră sau despre cum să îl administrați, vă rugăm să vizitați pagina Contactați-ne sau să ne sunați la (877) 778-0318.

HIPAA Compliant

Prin trimitere, sunteți de acord cu AmeriPharma Termeni de utilizare, Politica de confidențialitateși Notificare privind practicile de confidențialitate

ro_RORomanian